Mereo BioPharma Group (MREO) Competitors

$0.25 +0.01 (+4.33%)

As of 11:09 AM Eastern

MREO vs. ABOS, CNTN, TLSA, ADAG, and MOLN

Should you be buying Mereo BioPharma Group stock or one of its competitors? The main competitors of Mereo BioPharma Group include Acumen Pharmaceuticals (ABOS), Hillstream Biopharma (CNTN), Tiziana Life Sciences (TLSA), Adagene (ADAG), and Molecular Partners (MOLN). These companies are all part of the "pharmaceutical products" industry.

How does Mereo BioPharma Group compare to Acumen Pharmaceuticals?

Mereo BioPharma Group (NASDAQ:MREO) and Acumen Pharmaceuticals (NASDAQ:ABOS) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, dividends, earnings, valuation, institutional ownership, risk, profitability and analyst recommendations.

Mereo BioPharma Group has higher revenue and earnings than Acumen Pharmaceuticals. Mereo BioPharma Group is trading at a lower price-to-earnings ratio than Acumen Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mereo BioPharma Group	$500K	80.77	-$41.88M	-$0.06	N/A
Acumen Pharmaceuticals	N/A	N/A	-$121.33M	-$2.01	N/A

In the previous week, Acumen Pharmaceuticals had 4 more articles in the media than Mereo BioPharma Group. MarketBeat recorded 8 mentions for Acumen Pharmaceuticals and 4 mentions for Mereo BioPharma Group. Mereo BioPharma Group's average media sentiment score of 0.93 beat Acumen Pharmaceuticals' score of 0.47 indicating that Mereo BioPharma Group is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mereo BioPharma Group	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Acumen Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Mereo BioPharma Group's return on equity of -83.02% beat Acumen Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mereo BioPharma Group	N/A	-83.02%	-72.68%
Acumen Pharmaceuticals	N/A	-111.26%	-75.67%

Mereo BioPharma Group currently has a consensus target price of $3.25, indicating a potential upside of 1,184.58%. Acumen Pharmaceuticals has a consensus target price of $6.67, indicating a potential upside of 164.03%. Given Mereo BioPharma Group's higher possible upside, analysts plainly believe Mereo BioPharma Group is more favorable than Acumen Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mereo BioPharma Group	1 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25
Acumen Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

62.8% of Mereo BioPharma Group shares are owned by institutional investors. Comparatively, 71.0% of Acumen Pharmaceuticals shares are owned by institutional investors. 6.5% of Mereo BioPharma Group shares are owned by company insiders. Comparatively, 7.1% of Acumen Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Mereo BioPharma Group has a beta of 0.24, meaning that its stock price is 76% less volatile than the broader market. Comparatively, Acumen Pharmaceuticals has a beta of 0.32, meaning that its stock price is 68% less volatile than the broader market.

Summary

Mereo BioPharma Group beats Acumen Pharmaceuticals on 7 of the 13 factors compared between the two stocks.

How does Mereo BioPharma Group compare to Hillstream Biopharma?

Mereo BioPharma Group (NASDAQ:MREO) and Hillstream Biopharma (NASDAQ:CNTN) are both small-cap pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, dividends, earnings, institutional ownership, risk, profitability, valuation and analyst recommendations.

Mereo BioPharma Group has a beta of 0.24, meaning that its share price is 76% less volatile than the broader market. Comparatively, Hillstream Biopharma has a beta of 1.44, meaning that its share price is 44% more volatile than the broader market.

62.8% of Mereo BioPharma Group shares are owned by institutional investors. Comparatively, 1.2% of Hillstream Biopharma shares are owned by institutional investors. 6.5% of Mereo BioPharma Group shares are owned by company insiders. Comparatively, 6.7% of Hillstream Biopharma shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Hillstream Biopharma's return on equity of -35.59% beat Mereo BioPharma Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mereo BioPharma Group	N/A	-83.02%	-72.68%
Hillstream Biopharma	N/A	-35.59%	-27.05%

Mereo BioPharma Group currently has a consensus target price of $3.25, indicating a potential upside of 1,184.58%. Given Mereo BioPharma Group's stronger consensus rating and higher possible upside, equities analysts clearly believe Mereo BioPharma Group is more favorable than Hillstream Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mereo BioPharma Group	1 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25
Hillstream Biopharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Hillstream Biopharma has lower revenue, but higher earnings than Mereo BioPharma Group. Mereo BioPharma Group is trading at a lower price-to-earnings ratio than Hillstream Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mereo BioPharma Group	$500K	80.77	-$41.88M	-$0.06	N/A
Hillstream Biopharma	N/A	N/A	-$35.92M	-$3.99	N/A

In the previous week, Mereo BioPharma Group had 1 more articles in the media than Hillstream Biopharma. MarketBeat recorded 4 mentions for Mereo BioPharma Group and 3 mentions for Hillstream Biopharma. Mereo BioPharma Group's average media sentiment score of 0.93 equaled Hillstream Biopharma'saverage media sentiment score.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Mereo BioPharma Group	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Hillstream Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Mereo BioPharma Group beats Hillstream Biopharma on 7 of the 13 factors compared between the two stocks.

How does Mereo BioPharma Group compare to Tiziana Life Sciences?

Tiziana Life Sciences (NASDAQ:TLSA) and Mereo BioPharma Group (NASDAQ:MREO) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, risk, analyst recommendations, profitability, institutional ownership, dividends and earnings.

Tiziana Life Sciences' return on equity of 0.00% beat Mereo BioPharma Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tiziana Life Sciences	N/A	N/A	N/A
Mereo BioPharma Group	N/A	-83.02%	-72.68%

62.8% of Mereo BioPharma Group shares are owned by institutional investors. 39.8% of Tiziana Life Sciences shares are owned by company insiders. Comparatively, 6.5% of Mereo BioPharma Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Tiziana Life Sciences has a beta of 0.42, meaning that its share price is 58% less volatile than the broader market. Comparatively, Mereo BioPharma Group has a beta of 0.24, meaning that its share price is 76% less volatile than the broader market.

Tiziana Life Sciences has higher earnings, but lower revenue than Mereo BioPharma Group.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tiziana Life Sciences	N/A	N/A	-$18.43M	N/A	N/A
Mereo BioPharma Group	$500K	80.77	-$41.88M	-$0.06	N/A

In the previous week, Mereo BioPharma Group had 3 more articles in the media than Tiziana Life Sciences. MarketBeat recorded 4 mentions for Mereo BioPharma Group and 1 mentions for Tiziana Life Sciences. Tiziana Life Sciences' average media sentiment score of 1.89 beat Mereo BioPharma Group's score of 0.93 indicating that Tiziana Life Sciences is being referred to more favorably in the media.

Company	Overall Sentiment
Tiziana Life Sciences	Very Positive
Mereo BioPharma Group	Positive

Mereo BioPharma Group has a consensus target price of $3.25, indicating a potential upside of 1,184.58%. Given Mereo BioPharma Group's stronger consensus rating and higher possible upside, analysts plainly believe Mereo BioPharma Group is more favorable than Tiziana Life Sciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tiziana Life Sciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Mereo BioPharma Group	1 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Tiziana Life Sciences and Mereo BioPharma Group tied by winning 6 of the 12 factors compared between the two stocks.

How does Mereo BioPharma Group compare to Adagene?

Adagene (NASDAQ:ADAG) and Mereo BioPharma Group (NASDAQ:MREO) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, media sentiment, risk, profitability and institutional ownership.

Adagene's return on equity of 0.00% beat Mereo BioPharma Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Adagene	N/A	N/A	N/A
Mereo BioPharma Group	N/A	-83.02%	-72.68%

9.5% of Adagene shares are owned by institutional investors. Comparatively, 62.8% of Mereo BioPharma Group shares are owned by institutional investors. 21.2% of Adagene shares are owned by company insiders. Comparatively, 6.5% of Mereo BioPharma Group shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Adagene has a beta of 0.57, indicating that its stock price is 43% less volatile than the broader market. Comparatively, Mereo BioPharma Group has a beta of 0.24, indicating that its stock price is 76% less volatile than the broader market.

Adagene has higher revenue and earnings than Mereo BioPharma Group.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adagene	$7.67M	22.33	-$17.61M	N/A	N/A
Mereo BioPharma Group	$500K	80.77	-$41.88M	-$0.06	N/A

In the previous week, Adagene and Adagene both had 4 articles in the media. Adagene's average media sentiment score of 1.07 beat Mereo BioPharma Group's score of 0.93 indicating that Adagene is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Adagene	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Mereo BioPharma Group	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Adagene currently has a consensus price target of $8.00, indicating a potential upside of 121.36%. Mereo BioPharma Group has a consensus price target of $3.25, indicating a potential upside of 1,184.58%. Given Mereo BioPharma Group's higher probable upside, analysts clearly believe Mereo BioPharma Group is more favorable than Adagene.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adagene	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	2 Strong Buy rating(s)	3.00
Mereo BioPharma Group	1 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25

Summary

Adagene beats Mereo BioPharma Group on 9 of the 13 factors compared between the two stocks.

How does Mereo BioPharma Group compare to Molecular Partners?

Mereo BioPharma Group (NASDAQ:MREO) and Molecular Partners (NASDAQ:MOLN) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, media sentiment, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.

In the previous week, Mereo BioPharma Group had 3 more articles in the media than Molecular Partners. MarketBeat recorded 4 mentions for Mereo BioPharma Group and 1 mentions for Molecular Partners. Molecular Partners' average media sentiment score of 1.89 beat Mereo BioPharma Group's score of 0.93 indicating that Molecular Partners is being referred to more favorably in the news media.

Company	Overall Sentiment
Mereo BioPharma Group	Positive
Molecular Partners	Very Positive

Mereo BioPharma Group has a beta of 0.24, indicating that its share price is 76% less volatile than the broader market. Comparatively, Molecular Partners has a beta of 1.08, indicating that its share price is 8% more volatile than the broader market.

Mereo BioPharma Group has higher earnings, but lower revenue than Molecular Partners. Mereo BioPharma Group is trading at a lower price-to-earnings ratio than Molecular Partners, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Mereo BioPharma Group	$500K	80.77	-$41.88M	-$0.06	N/A
Molecular Partners	$5.65M	29.46	-$74.41M	-$1.99	N/A

Molecular Partners' return on equity of -60.62% beat Mereo BioPharma Group's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Mereo BioPharma Group	N/A	-83.02%	-72.68%
Molecular Partners	N/A	-60.62%	-51.84%

Mereo BioPharma Group presently has a consensus price target of $3.25, indicating a potential upside of 1,184.58%. Molecular Partners has a consensus price target of $8.38, indicating a potential upside of 103.18%. Given Mereo BioPharma Group's higher possible upside, equities analysts plainly believe Mereo BioPharma Group is more favorable than Molecular Partners.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Mereo BioPharma Group	1 Sell rating(s)	4 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.25
Molecular Partners	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

62.8% of Mereo BioPharma Group shares are held by institutional investors. Comparatively, 26.6% of Molecular Partners shares are held by institutional investors. 6.5% of Mereo BioPharma Group shares are held by insiders. Comparatively, 5.9% of Molecular Partners shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Mereo BioPharma Group beats Molecular Partners on 8 of the 14 factors compared between the two stocks.

Get Mereo BioPharma Group News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MREO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MREO vs. The Competition

Export

Metric	Mereo BioPharma Group	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$40.70M	$3.41B	$6.24B	$12.14B
Dividend Yield	N/A	2.25%	2.78%	5.23%
P/E Ratio	-4.25	15.32	20.67	25.38
Price / Sales	80.77	304.64	547.41	75.53
Price / Cash	N/A	56.93	27.81	36.29
Price / Book	0.97	6.83	9.59	6.65
Net Income	-$41.88M	$24.11M	$3.54B	$333.19M
7 Day Performance	-9.22%	-1.58%	-0.45%	-0.55%
1 Month Performance	-23.10%	3.84%	5.68%	7.66%
1 Year Performance	-89.88%	70.95%	38.47%	35.65%

Mereo BioPharma Group Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MREO Mereo BioPharma Group	3.6908 of 5 stars	$0.25 +4.3%	$3.25 +1,184.6%	-89.9%	$40.70M	$500K	N/A	40	News Coverage Earnings Report
ABOS Acumen Pharmaceuticals	2.275 of 5 stars	$2.49 +0.2%	$6.67 +168.3%	+162.2%	$179.49M	N/A	N/A	20	News Coverage Positive News Earnings Report
CNTN Hillstream Biopharma	0.7119 of 5 stars	$3.15 -0.3%	N/A	N/A	$178.48M	N/A	N/A	2	News Coverage
TLSA Tiziana Life Sciences	1.0054 of 5 stars	$1.39 -0.1%	N/A	-1.0%	$176.76M	N/A	N/A	8
ADAG Adagene	3.2191 of 5 stars	$3.70 +1.1%	$8.00 +116.2%	+136.9%	$176.05M	$7.67M	N/A	260	Positive News Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:MREO) was last updated on 5/12/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Mereo BioPharma Group (MREO) Competitors

MREO vs. ABOS, CNTN, TLSA, ADAG, and MOLN

How does Mereo BioPharma Group compare to Acumen Pharmaceuticals?

Summary

How does Mereo BioPharma Group compare to Hillstream Biopharma?

Summary

How does Mereo BioPharma Group compare to Tiziana Life Sciences?

Summary

How does Mereo BioPharma Group compare to Adagene?

Summary

How does Mereo BioPharma Group compare to Molecular Partners?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MREO vs. The Competition

Mereo BioPharma Group Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Mereo BioPharma Group (MREO) Competitors

MREO vs. ABOS, CNTN, TLSA, ADAG, and MOLN

How does Mereo BioPharma Group compare to Acumen Pharmaceuticals?

Which has stronger earnings and valuation, MREO or ABOS?

Does the media favor MREO or ABOS?

Is MREO or ABOS more profitable?

Do analysts recommend MREO or ABOS?

Do institutionals and insiders believe in MREO or ABOS?

Which has more risk and volatility, MREO or ABOS?

Summary

How does Mereo BioPharma Group compare to Hillstream Biopharma?

Which has more volatility & risk, MREO or CNTN?

Do institutionals and insiders believe in MREO or CNTN?

Is MREO or CNTN more profitable?

Do analysts recommend MREO or CNTN?

Which has higher earnings & valuation, MREO or CNTN?

Does the media refer more to MREO or CNTN?

Summary

How does Mereo BioPharma Group compare to Tiziana Life Sciences?

Is TLSA or MREO more profitable?

Do institutionals & insiders believe in TLSA or MREO?

Which has more volatility & risk, TLSA or MREO?

Which has stronger valuation & earnings, TLSA or MREO?

Does the media prefer TLSA or MREO?

Do analysts rate TLSA or MREO?

Summary

How does Mereo BioPharma Group compare to Adagene?

Is ADAG or MREO more profitable?

Do institutionals & insiders hold more shares of ADAG or MREO?

Which has more risk and volatility, ADAG or MREO?

Which has higher valuation & earnings, ADAG or MREO?

Does the media prefer ADAG or MREO?

Do analysts prefer ADAG or MREO?

Summary

How does Mereo BioPharma Group compare to Molecular Partners?

Does the media favor MREO or MOLN?

Which has more risk and volatility, MREO or MOLN?

Which has better earnings and valuation, MREO or MOLN?

Is MREO or MOLN more profitable?

Do analysts recommend MREO or MOLN?

Do insiders and institutionals believe in MREO or MOLN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MREO vs. The Competition

Mereo BioPharma Group Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools